Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Selected as Preferred Partner for UK's 100,000 Genomes Project

NEW YORK (GenomeWeb) – Illumina said in a regulatory filing this week that Genomics England has selected Illumina Cambridge as a preferred partner for the 100,000 Genomes Project.

The project was created by the UK government in late 2012 to sequence the genomes of up to 100,000 people in an effort to gain a better insight into cancer and other diseases and to better treat them. Genomics England, a company owned by the UK Department of Health, was set up to run the 100,000 Genomes Project.

Illumina Cambridge, a subsidiary of the San Diego-based company, was selected by Genomics England as a preferred partner for the sequencing part of the project, Illumina said in a document filed with the US Securities and Exchange Commission, adding that a definitive agreement is being worked out.

Last fall, Genomics England, Illumina, and the University of Cambridge said that they would sequence 10,000 whole genomes of children and adults with rare genetic diseases as part of a pilot project under the 100,000 Genomes Project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.